Artiva Biotherapeutics Replaces Underwater Stock Options with RSUs for Key Executives

Reuters
Dec 13, 2025
<a href="https://laohu8.com/S/ARTV">Artiva Biotherapeutics</a> Replaces Underwater Stock Options with RSUs for Key Executives

Artiva Biotherapeutics Inc. has implemented a new equity compensation arrangement for select employees, including President and CEO Fred Aslan and COO Jennifer Bush. Under Option for RSU Exchange Agreements, eligible participants were given a one-time opportunity to exchange outstanding stock options with exercise prices above the current market value for restricted stock units (RSUs) granted under the 2024 Equity Incentive Plan. As part of the exchange, Dr. Aslan surrendered options for 869,136 shares and received an equivalent number of RSUs, while Ms. Bush exchanged options for 84,877 shares for RSUs. The RSUs granted in exchange for vested options will vest in installments between August 2026 and February 2027, with full acceleration possible upon certain termination events. RSUs granted for unvested options will vest between August 2026 and February 2029, with partial acceleration in specific circumstances. The RSU grants became effective on December 12, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-317784), on December 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10